SCHEMBL6444222

SCHEMBL6444222

N#Cc1c(NCCN2CCOCC2)nc(N)nc1-c1ccco1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 14/20 0.63
KDM4E B2RXH2 12/20 0.63
HPGD P15428 9/20 0.63
NPSR1 Q6W5P4 1/20 0.63
GAA P10253 6/20 0.56
HSD17B10 Q99714 3/20 0.56
LMNA P02545 2/20 0.51
POLB P06746 1/20 0.51
SMARCA2 P51531 1/20 0.51
PKM P14618 1/20 0.50
ADORA2A P29274 2/20 0.49
ADORA2B P29275 2/20 0.49
ADORA1 P30542 2/20 0.49
GLA P06280 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
HIF1A Q16665 1/20 0.45
ACHE P22303 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6446329 0.91 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDNPSR1GAA
SCHEMBL6445232 0.85 ACHE (0.56) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL7147054 0.85 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDNPSR1GAA
SCHEMBL7178584 0.85 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDNPSR1GAA
SCHEMBL6443228 0.81 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDNPSR1GAA
SCHEMBL6441991 0.81 ADORA2A (0.57) ALDH1A1KDM4EHPGDNPSR1GAA
SCHEMBL7151238 0.80 ADORA2A (0.53) ALDH1A1KDM4EHPGDNPSR1GAA
SCHEMBL6441656 0.80 ADORA1 (0.49) ALDH1A1KDM4EHPGDNPSR1GAA
SCHEMBL6446015 0.79 ADORA2A (0.61) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL5036673 0.79 ADORA2A (0.61) ALDH1A1KDM4EHPGDNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885KDM4E 3250/4885HPGD 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.